SCHEMBL18924315

SCHEMBL18924315

CC(C)(C)Cc1ccnc(NS(C)(=O)=O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.42
KDM4E B2RXH2 6/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
NR3C2 P08235 1/20 0.41
LMNA P02545 2/20 0.40
KIT P10721 1/20 0.37
BRAF P15056 1/20 0.37
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HCK P08631 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK14 Q16539 1/20 0.36
SCN9A Q15858 1/20 0.36
KDM4D Q6B0I6 1/20 0.36
TGFBR1 P36897 2/20 0.35
SLC22A12 Q96S37 1/20 0.35
GLA P06280 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25847426 0.82 KDM4E (0.51) IGF1RKDM4EALDH1A1HPGDLMNA
SCHEMBL4307544 0.81 KDM4E (0.43) IGF1RKDM4EALDH1A1HPGDLMNA
SCHEMBL3126650 0.81 LOXL2 (0.45) IGF1RKDM4EALDH1A1HPGDNR3C2
SCHEMBL20052278 0.78 NR3C2 (0.43) IGF1RNR3C2
SCHEMBL12315314 0.76 KDM4E (0.42) KDM4EALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL12203063 0.76 ALDH1A1 (0.52) KDM4EALDH1A1HPGDNR3C2LMNA
SCHEMBL18857808 0.76 CCR1 (0.34) NR3C2LMNASMN1; SMN2SCN9AL3MBTL1
SCHEMBL18924326 0.75 KDM4E (0.40) IGF1RKDM4EALDH1A1HPGDLMNA
SCHEMBL12460797 0.73 KDM4E (0.59) KDM4EALDH1A1HPGDLMNAPOLB
SCHEMBL21617733 0.71 BRD4 (0.49) KDM4EALDH1A1HPGDLMNASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183015-B2 Heterocyclic compounds and methods of use MEDIVATION TECHNOLOGIES LLC (US) 2019-01-22 US disclosed
US-20180028518-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES LLC 2018-02-01 US disclosed
US-9670172-B2 Heterocyclic compounds and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2017-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180028518-A1 Heterocyclic Compounds and Methods of Use LIPC, CPT1A, FABP1 IGF1R 272/4885KDM4E 2233/4885ALDH1A1 779/4885
US-10183015-B2 Heterocyclic compounds and methods of use LIPC, CPT1A, FABP1 IGF1R 272/4885KDM4E 2233/4885ALDH1A1 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.